drugset
drugset / Trial / NCT03375632

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

NCT03375632 ↗

Phase 1 Completed 26 enrolled Mochida Pharmaceutical Company, Ltd. Fuji Yakuhin Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.

Timeline

Start
2018-01-04
Primary completion
2018-05-29
Completion
2018-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dotinurad Small molecule — Oral

Indications

gout